

Curriculum Vitae

Date: August 2, 2008

Name and Terminal Degree(s):

Michael Parks Bogenschutz, M.D.

Professional Address including Department:

University of New Mexico School of Medicine
Department of Psychiatry
2400 Tucker NE
Albuquerque, NM 87131
(505)-272-8428

Home Address

807 Parkland Circle SE
Albuquerque, NM 87108

Licensure(s) with Date(s)

1994: to present: New Mexico unlimited medical license #94-195
1992 to 1995: Massachusetts unlimited medical license #75052

Certification(s) with Date(s)

2004: ASAM certified in Addiction Medicine, #616278
1997: ABPN certified in Addiction Psychiatry, #1085 (recertified August 2007)
1995: Diplomate of the American Board of Psychiatry and Neurology, #41647 (recertified August 2005)
1991: Diplomate of the National Board of Medical Examiners

Educational History:

1985-1990: Doctor of Medicine, *cum laude*, Harvard Medical School and Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston and Cambridge Massachusetts
1982-1985: Bachelor of Arts, *cum laude*, Harvard College, Cambridge, Massachusetts.

Employment History - principal positions since the terminal degree

7/2006 to present: Professor of Psychiatry at University of New Mexico School of Medicine
7/2006 to present: Adjunct Professor of Psychology, University of New Mexico
6/2004 to present: Addiction Psychiatry Fellowship Director, University of New Mexico School of Medicine

11/2001 to present: Vice Chair for Addiction Psychiatry, Department of Psychiatry, University of New Mexico School of Medicine
7/2000 to 6/2006: Associate Professor of Psychiatry at University of New Mexico School of Medicine
5/2000 to 8/2001: Director of Continuing Care Clinics, University of New Mexico Mental Health Center
7/1998-3/2000: Co-Director of Partial Hospital Program, University of New Mexico Mental Health Center
8/1995 to 1/2003: Medical Director, Dual Diagnosis Treatment Program, University of New Mexico Mental Health Center
8/1994 to 6/2000: Assistant Professor of Psychiatry at University of New Mexico School of Medicine
1996 to 1997: Consulting Psychiatrist for Student Mental Health Services, University of New Mexico
1990-1994: Residency in Adult Psychiatry, The Cambridge Hospital, Cambridge, Massachusetts

Professional recognition, honors, etc.

2007, 2005, 2003,
2001, 1998: Listed in "Best Doctors in America."®
2000: Rosenbaum Research Award (Awarded by Department of Psychiatry, University of New Mexico School of Medicine)
1999: Robert Kellner Teaching Award (Awarded by Adult Psychiatry Residents, University of New Mexico School of Medicine)
1998: Robert Kellner Teaching Award (Awarded by Adult Psychiatry Residents, University of New Mexico School of Medicine)
1998: Leonard Weisskopf Faculty Award (Awarded by Department of Psychiatry, University of New Mexico School of Medicine)
1982-1983: Harvard College National Scholarship.

Memberships in Professional Societies

2001 to present: Member of the American Academy of Addiction Psychiatry
1993 to present: Member of the American Psychiatric Association #071745

Other extramural professional activities

2003: Guest Editor for *Obstetrics and Gynecology Clinics of North America*
2000: Guest editor for *Academic Psychiatry*
1996-present: Ad hoc reviewing for journals:
Psychiatric Services
Academic Psychiatry
Canadian Medical Association Journal
Addictive Behaviors
Journal of Clinical Psychiatry

General Hospital Psychiatry
American Journal of Psychiatry
Journal of Consulting and Clinical Psychology
Journal of Dual Diagnosis
Journal of Substance Abuse Treatment
Alcohol Research and Health

Invited lectures

- Bogenschutz, M.P.** Clinical lessons learned from New Mexico participation in 0010. NIDA conference: Young Adult Buprenorphine Treatment Hand-Off Meeting, Feb 28, 2008.
- Bogenschutz, M. P.** Exploring local variation in methamphetamine use in Native communities: a New Mexico perspective. NIDA conference: Methamphetamine Abuse in American Indian and Alaska Native Populations. Washington DC, Sept 20-21, 2007.
- Bogenschutz, M. P.** Buprenorphine: A New Option for Treatment of Opioid Dependence. Department of Family and Community Medicine Grand Rounds, University of New Mexico School of Medicine, April 5, 2006, Albuquerque, NM
- Bogenschutz, M. P.** 12-step approaches for the dually diagnosed. UNM SOM Department of Psychiatry Grand Rounds, Albuquerque, NM, 17 Feb 2006:
- Bogenschutz, M. P.** 12-step Approaches for the Dually Diagnosed: Mechanisms of Change. Presentation at The Search for Mechanisms of Change in Evidence-Based Behavioral Treatments, Satellite Pre-Conference 1-Day Workshop, 28th Annual Research Society on Alcoholism, Santa Barbara, CA, June 25, 2005
- Bogenschutz, M. P.** Pharmacotherapy for Addictions. Department of Family and Community Medicine Grand Rounds, University of New Mexico School of Medicine, August 11, 2004, Albuquerque, NM
- Bogenschutz, M. P.** 12-step Approaches for the Dually Diagnosed: a Literature Review. Complexities of Co-Occurring Conditions Conference, June 24, 2004, Washington, DC.
- Bogenschutz, M. P.:** Alcohol Dependence-A Review of Pharmacotherapies, Southwest Psychiatric Symposium, 10/11/03, Albuquerque, NM
- Bogenschutz, M. P.:** Pharmacotherapy for Addictions. Department of Family and Community Medicine Grand Rounds, University of New Mexico School of Medicine, 5/29/02
- Bogenschutz M. P.:** 12 Step Approaches for the Dually Diagnosed. Southwest Psychiatric Symposium, 11/3/01, Hyatt Regency Hotel, Albuquerque, NM
- Bogenschutz M. P.:** 12 Step Participation Among Dual Diagnosis Patients, Psychiatry Grand Rounds, University of New Mexico Health Sciences Center, 12/11/98.

- Bogenschutz M. P.:** New Developments in the Basic Science and Pharmacologic Treatment of Addictions, Internal Medicine Grand Rounds, University of New Mexico Health Sciences Center, 1/15/98.
- Bogenschutz, M. P.:** Measurement of Illness-related Beliefs in Comorbid Psychotic Illness and Substance Use Disorder (Dual Diagnosis). American Psychiatric Association Research Colloquium for Young Investigators, New York, NY, 1996.
- Bogenschutz, Michael P.** Alcohol Withdrawal Management. Grand Rounds, Las Vegas State Hospital, Las Vegas, New Mexico, February, 1995

Scholarly achievements:

Volumes edited or co-edited:

Bogenschutz, M. P., Rayburn, W. F., Guest Editors: Substance Use Disorders and Women's Health (Obstetrics and Gynecology Clinics of North America, Volume 30, Number 3), W. B. Saunders Company, Philadelphia, PA, 2003.

Bogenschutz, M. P., Roberts, L. W., Guest Editors: Preparing the Next Generation of Psychiatric Researchers (Academic Psychiatry, Volume 25, Number 1), American Psychiatric Press, Washington, DC, 2001.

Original research or scholarly articles in refereed journals:

Geppert, C. M. A., **Bogenschutz, M. P.** (2009) Pharmacological Research on Addictions: A Framework for Ethical and Policy Considerations. *Journal of Psychoactive Drugs* 41 (1) 49-60.

Woody, G. E., Poole S. A., Subramaniam, G., Dugosh, K., **Bogenschutz, M.**, Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., Forman, R., Vetter, V., McNicholas, L., Blaine, J., Lynch, K. G., Fudala, P. (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. *JAMA* 300, 2003-2011.

Bogenschutz, M. P., Tonigan, J. S., Pettinati, H.M. (2008) Effects of alcoholism typology on response to naltrexone in the COMBINE trial. *Alcoholism: Clinical and Experimental Research* 32 (12) 1-9.

Bogenschutz, M. P., DeMarzo, L., Roll, J. (2008). Response: anticipating new medications. *Addiction Science & Clinical Practice* 2 (4), 36-38.

Bogenschutz, M.P. (2007) 12-step approaches for the dually diagnosed: mechanisms of change. *Alcoholism: Clinical and Experimental Research* 31 (S3), 64S-66S.

Miller, W. R., **Bogenschutz, M. P.** (2007) Spirituality and Addiction. *Southern Medical Journal* 100 (4):433-436.

Geppert, C., **Bogenschutz, M. P.**, Miller W. R. (2007) Development of a Bibliography on Spirituality and Addictions. *Drug and Alcohol Review* 26, 389-395.

Tonigan, J. S., **Bogenschutz, M. P.**, & Miller, W. R. (2006). Is alcoholism typology a predictor of both AA affiliation and disaffiliation after treatment? *Journal of Substance Abuse Treatment*, 30, 323-330.

Bogenschutz, M. P., Tonigan, J. S., & Miller, W. R. (2006). Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change. *Journal of Studies on Alcohol*, 67, 562-567.

Miller, W.R, **Bogenschutz, M. P.**, Villarreal, I. (2006). Research and practice together: The NIDA Clinical Trials Network. *Adicciones* 18 (1), 11-22.

Bogenschutz M. P., Geppert, C. M. A., George, J. (2006) The role of 12-step approaches in dual diagnosis treatment and recovery. *American Journal on Addictions* 15 (1), 50-60.

- Lu, B., Coberly, R., **Bogenschutz, M. P.** (2005) Use of oxcarbazepine in outpatient alcohol detoxification *American Journal on Addictions* 14, 191-192.
- Bogenschutz, M. P.** (2005) Specialized 12-step programs and 12-step facilitation for the dually diagnosed. *Community Mental Health Journal* 41 (1), 7-19.
- Rayburn, W. F., **Bogenschutz, M. P.** (2004). Pharmacotherapy for pregnant women with addictions. *American Journal of Obstetrics and Gynecology* 191 (6), 1885-1897.
- Bogenschutz M. P.**, Nurnberg, H. G. (2004) Olanzapine versus Placebo in the Treatment of Borderline Personality Disorder. *Journal of Clinical Psychiatry* 65 (1), 104-109.
- Bustillo, J., Lauriello, J., Parker, K., Hammond, R., Rowland, L., **Bogenschutz, M.**, Keith, S. (2003) Treatment of weight gain with fluoxetine in olanzapine treated schizophrenic outpatients. *Neuropsychopharmacology*, 28, 527-529.
- Bogenschutz, M. P.** (2001) Drugs on the internet. [Letter] *American Journal of Psychiatry*. 158 (12), 2094-5.
- Nurnberg, H. G., Hensley, P. L., **Bogenschutz, M. P.** (2001) Cost Effectiveness of SSRI Antidepressants: A Dose Stratification Approach for Agent Cost Comparisons. *Drug Benefit Trends* 13, 7-13.
- Nurnberg, H. G., Hensley, P. L., Lauriello, J., **Bogenschutz, M. P.** (2001) Sildenafil treatment of SSRI and other antidepressant associated sexual dysfunction: a 12 case treatment replication in a naturalistic clinical setting. *Primary Psychiatry* 8 (4), 69-78.
- Pyeovich, D., **Bogenschutz, M. P.** (2001) Herbal diuretics and lithium toxicity. [Letter] *American Journal of Psychiatry* 158 (8), 1329.
- Bogenschutz, M. P.**, Quinn, D. (2001) Acronyms for substance use disorders. [Letter] *Journal of Clinical Psychiatry* 62 (6), 474-475.
- Bogenschutz, M. P.**, Nurnberg, H. G. (2000): Theoretical and Methodological Issues in Psychiatric Comorbidity. *Harvard Review of Psychiatry*, 8 (1), 18-24.
- Bogenschutz, M. P.**, Akin, S. J. (2000) 12 Step Participation and Attitudes Toward 12 Step Programs in Dual Diagnosis Patients. *Alcoholism Treatment Quarterly* 18 (4), 31-45.
- Bogenschutz, M. P.** (2000) Drug Information Libraries on the Internet. *Journal of Psychoactive Drugs* 32 (3), 249-258.
- Nurnberg, H. G., Woodbury, M., **Bogenschutz, M. P.** (1999) A Mathematical Typology Analysis Of DSM-III-R Personality Disorder Classification: Grade Of Membership Technique. *Comprehensive Psychiatry* 40 (1), 61-71.
- Blanchard, J. J., Squires, D., Henry, T., Horan, W. P., **Bogenschutz, M.**, Lauriello, J., Bustillo, J. (1999) Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. *Journal of Nervous and Mental Disease* 187 (2), 72-79.
- Bogenschutz, M. P.**, Siegfried, S. L. (1998) Factors Affecting Engagement in Dual Diagnosis Treatment. *Psychiatric Services* 49,1350-1352.

Bogenschutz, M. P., Nurnberg, H. G. (1996) Effects of sertraline in the treatment of alcoholism: 12 month pilot results. *American Journal on Addictions* 5, 91.

Wilson, C. M., Serrano, A. E., Wasley, A., **Bogenschutz, M. P.**, Shankar, A. H., Wirth, D. F. (1989) Amplification of a gene related to mammalian mdr genes in drug-resistant *Plasmodium falciparum*. *Science* 224 (4909), 1184-1186.

Review articles and articles appearing as chapters in edited volumes:

Geppert, CMA, **Bogenschutz, M. P.** (2009) Substance-Related Disorders. In *Clinical Psychiatry Essentials*, Roberts L. W., Hoop, J. G., Heinrich T. W. Eds. pp 149-162. Baltimore, MD, Lippincott Williams and Wilkins.

Geppert, C. M. A., **Bogenschutz, M. P.** Ethics in substance use disorder treatment (2009) *Psychiatric Clinics of North America* 32 (2) 283-297.

Bogenschutz, M. P. (2008) Individual and Contextual Factors that Influence AA Affiliation and Outcomes. In *Recent Developments in Alcoholism Volume 18: Alcoholics Anonymous and Spiritual Aspects of Addiction Recovery*. pp 413-433. Marc Galanter and Lee Ann Kaskutis, Eds. New York, NY, Springer.

Venner, K. L., **Bogenschutz, M. P.** (2008) Cultural and Spiritual Dimensions of Addictions Treatment. In *The Book of Ethics: Expert Guidance for Professionals who Treat Addiction*, Geppert C. M. A., Roberts, L. W., eds., pp. 67-85. Center City, Minnesota: Hazelden.

Geppert, C. M. A., **Bogenschutz, M.** (2004) Women with Addiction Disorders: Ethical Issues. In *The Encyclopedia of Women's Health* (M Sajatovic, S Loue, Eds). New York: Kluwer Academic/Plenum Publishing.

Bogenschutz, M., Roberts, L. W., & Dyer, A. R. (2004) Caring for People with Addictions. In L. W. Roberts & A. D. Dyer, *Ethics in Mental Health Care* (pp. 137-151). Washington, DC: American Psychiatric Publishing, Inc.

Bogenschutz, M. P., Rayburn, W. F. (2003) Substance use disorders and women's health. *Obstetrics and Gynecology Clinics of North America* 30, xi-xii.

Bogenschutz, M. P., Geppert, C. M. A. (2003) Pharmacologic Treatments for Women with Addictions. *Obstetrics and Gynecology Clinics of North America* 30, 523-544.

Roberts, L. W., **Bogenschutz, M. P.** (2001) Preparing the Next Generation of Psychiatric Researchers: A story of obstacles and optimism. *Academic Psychiatry*, 25 (1), 4-8.

Bogenschutz, M. P., Nurnberg, H. G. (1999) Classification of Mental Disorders, chapter in *Comprehensive Textbook of Psychiatry, 7th edition*, eds. Kaplan HI, Sadock BJ, Williams and Wilkins, Baltimore.

Other writings and scholarly products (not abstracts)

Nowinski, J., **Bogenschutz, M. P.** (2005) 12-Step Facilitation for Dual Diagnosis (TSFDD) Session Guidelines, unpublished manual.

Bogenschutz, M. P. (2002) Twelve-step Attitudes questionnaire for the dually Diagnosed (TSAQ-DD), unpublished instrument.

Bogenschutz, M. P. (2000) Self-medications beliefs questionnaire (SMBQ), unpublished instrument.

Bogenschutz, M. P., Nurnberg, H. G. (2002) Clinical Global Impression for Borderline Personality Disorder (CGI-BPD), unpublished instrument.

American Indian/Alaska Native Suicide Task Force (1996) American Indian/Alaska Native Suicide Task Force Report, Report submitted to HHS Secretary Donna Shalala and US Senator Pete Domenici 4/96.

Bogenschutz, M. P. (1990) Molecular Analysis of MDR-like Genes and RNA Transcripts in Drug-Resistant and Drug-Sensitive Strains of *Plasmodium falciparum*. M.D. Thesis, Harvard Medical School.

Works in progress:

Accepted for publication in peer-reviewed journals

Submitted for publication in peer-reviewed journals:

Bogenschutz, M. P., Abbott, P. J., Kushner, R., Tonigan, J. S., Woody, G. E. Effects of Buprenorphine and Hepatitis C on Liver Enzymes in Adolescents and Young Adults. Under review, Drug and Alcohol Dependence

Thoma, R. J., Ruhl, D., Mullins, P., Yeo, R. A., Caprihan, A., Monnig, M., Lysne, P. **Bogenschutz, M. P.** ; Tonigan, J. S., Gasparovic, C. (Under Review, ACER) Perturbation of the glutamate-glutamine system in alcohol dependence and remission.

Monnig, M., Caprihan, A., Yeo, R., Gasparovic, C., Ruhl, D., Lysne, P., Scott Tonigan, S., **Bogenschutz, M.**, Hutchinson, K., Thoma, R. J., (Under Review, Neuroimage) White matter integrity in alcohol dependence and remission Using tract-based spatial statistics.

Chapters accepted for publication:

Chapters submitted for publication:

Invited or refereed abstracts and/or presentations at professional meetings:

- Bogenschutz, M. P.**, Tonigan, J. S. (2008) Help-Seeking and Drinking Reduction: the Influence of Formal Treatment and AA Attendance. *American Journal on Addictions* XX (X) XXX.
- Bogenschutz, M. P.**, Kushner, R., Tonigan, J. S., Woody, G. E. (2008). Effects of Buprenorphine and Hepatitis C on Liver Enzymes in Adolescents and Young Adults. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 19. Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- Erickson, S. J., Tonigan, J. S., **Bogenschutz, M. P.** (2008) Therapist Effects in the Treatment of Pregnant Substance Abusers: Clinical Trials Network #13. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 53. Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- Foley, K., Pallas, D., **Bogenschutz, M. P.**, Forcehimes, A., Ph.D., Tonigan, J. S., Svikis, D. (2008). Treatment History and Job Seeking Behaviors in a Native American Sample. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 58. Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- Forcehimes, A., **Bogenschutz, M. P.**, J. Scott Tonigan, J. S. (2008). Impact of Therapeutic Alliance on Treatment Outcome in Opioid Dependent Adolescents: Young Adults Treated with Buprenorphine. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 59. Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- Tonigan, J. S., **Bogenschutz, M. P.**, Forcehimes, A. (2008) Changes in 12-step Cognitions and Practices Among Treatment Seeking Adolescents. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 189, Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- Venner, K. L., Erickson, S. J, **Bogenschutz, M. P.**, Tonigan, J. S. (2008). Investigating client response to the active ingredients of motivational interviewing. *College on Problems of Drug Dependence 2008 Abstract Book*, pg 193, Retrieved June 27, 2008 from <http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf>.
- M. P. Bogenschutz**, D. Pallas, K. Foley, R. Daw, J. S. Tonigan, A. Forcehimes, R. Chavez, D. S. Svikis (2008) Effect of Job Skills training on employment and job seeking behaviors in a Native American substance abuse treatment sample. *Alcoholism: Clinical and Experimental Research*: 32 (6, Supplement), 196A.
- Bogenschutz, M. P.**, Nowinski, J., Tonigan, J. S., Kushner, R., Vogel, H., Hume, D., Treacher, R., Hyde, R. (2008) Training and Fidelity monitoring of 12-step facilitation adapted for alcoholics with serious psychiatric disorders.

- Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 185A.
- Bogenschutz, M. P.**, Hume, D., Vogel, H., Nowinski, J., Baca, A., Tonigan, J. S. (2008) Enhancing 12-step participation among drinkers with serious mental illness. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 184A.
- Tonigan, J.S., **Bogenschutz, M. P.**, Roberta Chavez, Matt O’Nuska (2008) Reliability of self-report measures in seriously mentally ill alcoholics. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 187A.
- Bogenschutz, M. P.**, Pettinati, H. M., Anton, R.F., Tonigan J. S. (2008) Naltrexone, alcohol Subtypes, craving, and drinking outcome in the COMBINE trial. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 256A.
- Tonigan, J. S., **Bogenschutz, M. P.**, & Forcehimes, A. (2008) Readiness for change and AA attendance. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 184A.
- Tonigan, J. S., McCrady, B., **Bogenschutz, M. P.** & Forcehimes, A. (2008) A Re-examination of AA Attendance, Self-Efficacy, and Changes in Drinking. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 184A.
- Tonigan, J. S., **Bogenschutz, M. P.** & Forcehimes, A. A. (2008) Utilization of treatment and AA: relative contributions to early abstinence. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 184A.
- Monnig, M. A., Caprihan, A., Ruhl, D., Lysne, P., Gasparovic, C., Clark, V., Yeo, R. A., **Bogenschutz, M.**, & Thoma , R. J. (2008) Diffusion Tensor Imaging Reveals Callosal White Matter Abnormality in Alcohol Dependence and Recovery. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 169A.
- Pettinati, H. M., **Bogenschutz, M. P.**; Tonigan, J. S. (2008) Alcohol Subtypes and Differential Treatment Outcomes from the COMBINE Study. Alcoholism: Clinical and Experimental Research: 32 (6, Supplement), 281A.
- Woody, G., Poole, S., Subramaniam, G., **Bogenschutz, M.**, Patkar, A. Connery, H., Potter, J., Fudala, P., Dugosh, K., Lynch, K., Forman, R., Fishman, M., Abbott, P., Kushner, R., Publicker, M., McNicholas, L., Blaine, J. (Poster, American College of Neuropsychopharmacology, Boca Raton Florida, Dec 9-13, 2007) Buprenorphine treatment in opioid addicted adolescents/young adults.
- Bogenschutz, M. P.**, Tonigan, J. S. (2007). Counseling, AA, and Medical Treatment in Problem Drinkers. Abstract/oral presentation, AAAP 18th Annual Meeting, Nov. 29-Dec. 2, 2007.
- Bogenschutz, M. P.**, Tonigan, J.S. Is polysubstance use a predictor of AA disaffiliation? College on Problems of Drug Dependence 69th annual meeting, June 21, 2007.

- Woody, GE; Poole, S; Subramaniam, G; **Bogenschutz, M**; Publicker, M; Connery, H; Patkar, A; Forman, R; Glick, J; Blaine, J. (2007). Buprenorphine/Naloxone for Opioid Dependent Adolescents/Young Adults. Bekhterev International Jubilee conference, Addiction Psychiatry Satellite, May 15, 2007.
- Bogenschutz, M. P.**, Geppert, C. M. A., & Miller, W. R. (2006). Development of a comprehensive bibliography on spirituality and addictions. *Alcoholism: Clinical and Experimental Research*, 30(6, Supplement), 359. (Abstract).
- Clark, V.P., Anderson, R. E., England, R., Beatty, G., DiPasquale, T., Posse, S., Kodituwakku, P., Rosen, A., Phillips, J. P., Ricardo Blanco, R., Paul Hicks, P., **Michael P. Bogenschutz., M. P.**: A Multimodal Imaging Study of Relapse in Stimulant Dependence. Cognitive Neuroscience Society 2006 Meeting, April 8-11, 2006, San Francisco, CA.
- Bogenschutz, M. P.**, Tonigan, J. S., Miller, W. R. Examining Self-efficacy as a Mediator of AA's Effect on Abstinence: Moderating Effects of Alcoholism Typology. Accepted for Eleventh International Conference on Treatment of Addictive Behaviors (ICTAB-11) Santa Fe, New Mexico January 29 - February 2, 2006
- Bogenschutz, M. P.**, Tonigan, J. S. (2005) Does Alcoholism Typology Moderate AA-Related Self-Efficacy to Be Abstinent? *Alcoholism: Clinical and Experimental Research*, 29 (5, Supplement), 392.
- Tonigan, J. S., **Bogenschutz, M. P.** (2005) Is Family History of Alcoholism and Current Problem Severity a Predictor of Both AA Affiliation and Disaffiliation? *Alcoholism: Clinical and Experimental Research*, 29 (5, Supplement), 388.
- Wilbourne, P. L., Miller, W. R., Finney, J. W., Tonigan, J. S., **Bogenschutz, M.**, Johnson, W., & Daugherty, M. (2005). Measures of alcohol treatment outcome in randomized clinical trials: Prevalence and rates of statistical significance. *Alcoholism: Clinical and Experimental Research*, 29 (5, Supplement), 630.
- Wilbourne, P. L., Miller, W. R., Finney, J. W., **Bogenschutz, M.**, Smith, J. E., Daugherty, M., & Johnson, W. (2005). Mesa Grande and APA Division 12 guidelines: A comparative analysis of methods for assigning empirical support to treatments for alcohol problems. *Alcoholism: Clinical and Experimental Research*, 29 (5, Supplement), 662.
- Bogenschutz, M. P.**, Geppert C. M. A., George J. (2004) 12-step Approaches for the Dually Diagnosed: a Literature Review. Abstract, Complexities of Co-Occurring Conditions Conference, Washington, DC., June 23-25, 2004.
- Bogenschutz, M. P.**, Hensley, P. L., Geppert, C. M., Paine, S., Nurnberg, H. G. (2004) The clinical global improvement scale for borderline personality disorder. Abstract, American Psychiatric Association Annual Meeting, May 1-6, 2004.
- Bogenschutz, M.P.**, Locklin, S. (2003) Modified 12-step Facilitation for the Dually Diagnosed. Proceedings of AAAP 14th Annual Meeting, New Orleans, Louisiana, December 4-7, 2003

- Nurnberg, H. G., **Bogenschutz, M.** (2003) (NR756) Antipsychotic treatment of BPD: a 12-week, double-blind, placebo-control trial with olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association. San Francisco, CA.
- Bogenschutz, M. P.**, Vigil, J., Arenella, P. (2002) Attitudes of Dually Diagnosed Patients Toward Double Trouble in Recovery and Traditional 12-Step Programs. Proceedings of American Academy of Addiction Psychiatry Annual Meeting, Las Vegas NV, December 2002.
- Hensley, P. L., Nurnberg, H. G., **Bogenschutz, M. P.**, Paine, S. (2002) Hormone Effects in Female SSRI Sexual Dysfunction. Proceedings of the 155th annual Meeting of the American Psychiatric Association, New Research poster number 443, May 22, 2002.
- Nurnberg, H. G., Hensley, P. L., **Bogenschutz, M. P.** (2002) Hormone Effects In Female SRI-Associated Sexual Dysfunction. Proceedings of NIMH NCDEU 42nd Annual Meeting, Boca Raton FL, June 2002.
- Bogenschutz, M. P.**, Lauriello, J., Bustillo, J., Hammond, R. (2001) Olanzapine versus Haloperidol in the Treatment of Patients with Comorbid Schizophrenia and Active Substance Dependence. NIMH NCDEU 41st Annual Meeting, Phoenix, AZ, June 2001.
- Bogenschutz, M. P.**, Eizner, M., Bustillo, J., Lauriello, J. (2001) Nicotine and cotinine levels in schizophrenics with and without comorbid substance use disorder. NIMH NCDEU 41st Annual Meeting, Phoenix, AZ, June 2001.
- Eizner, M., **Bogenschutz, M. P.**, Bustillo, J. (2001) Nicotine and cotinine levels in schizophrenics with and without substance use disorder. American Psychiatric Association annual meeting, New Orleans, LA, May 5-10, 2001
- Conforti, K., **Bogenschutz, M. P.**, Handmaker, N. S., Braunstein, M., Paine, S. (2000) Reliability of substance-related questionnaires in severely mentally ill substance misusers. Research Society on Alcoholism, 23rd Annual Scientific Meeting, June 24-29, 2000.
- Bogenschutz, M. P.**, Vigil, J., Conforti, K. (2000) Self medication beliefs in mentally ill users of alcohol and other drugs. Research Society on Alcoholism, 23rd Annual Scientific Meeting, June 24-29, 2000.
- Nurnberg, H. G., Westerberg, V. S., **Bogenschutz, M.**, Tonigan, J. S., Sanchez, F. P., Tuason, V. B. (1995) Effects of Sertraline in the Treatment of Alcoholism: 12 Month Pilot Results of the ARTS Study. Proceedings of the Seventh International Conference on Treatment of Addictive Behaviors, Nijmegen, The Netherlands, 1995.

Abstracts Accepted for Publication

- Forcehimes, A. A., Houck, J. M., **Bogenschutz, M. P.**, Svikis, D., Foley, K. (CPDD 2009) Predictors of job seeking behaviors.

Abstracts Submitted for Publication

Contributed (unrefereed) abstracts and/or oral presentations at professional meetings:

Bogenschutz M. P., Lauriello J, Bustillo J, Hammond R: Olanzapine versus Haloperidol in the Treatment of Patients with Comorbid Schizophrenia and Active Substance Dependence, presented at Eli Lilly Investigator-Initiated Trials Conference, Dallas, TX, 2/3/01.

Bogenschutz MP: Measurement of Illness-related beliefs in Comorbid Psychotic Illness and Substance Use Disorder (Dual Diagnosis). Abstract, Proceedings of American Psychiatric Association Research Colloquium for Young Investigators, New York, NY, 1996.

Current Grant and Contract Funding:

Clinical Trials Network: Southwest Node (U10DA15833)
Michael P. Bogenschutz, P. I.
NIDA (NIH)
10/01/2002-8/31/2010

A Program of Research and Mentorship on Alcoholism and Co-occurring
Disorders (K24AA016555)
NIAAA (NIH)
Michael P. Bogenschutz, PI
09/20/2007 – 08/31/2012

12-step Facilitation for the Dually Diagnosed (R01AA015419)
Michael P. Bogenschutz, P.I.
NIAAA (NIH)
09/01/2005 - 05/31/2010

Pending Grant and Contract Funding

Administration of psilocybin to facilitate behavior change in alcohol dependence
1R01OD005700-01
NIH
Under review

12-Step Facilitation for the Dually Diagnosed 3R01AA015419-05S1,
NIAAA (NIH) (competitive revision)
Under review

Clinical Trials Network: Southwest Node 3U10DA015833-08S1
NIDA (NIH) (administrative Supplement)
Under review

A Program of Research and Mentorship on Alcoholism and Co-occurring
Disorders 3K24AA016555-02S1
NIAAA (NIH), Administrative Supplement,
Under review

Past Grant and Contract Funding

A transtheoretical model of AA-related behavior change (R01-AA014197-01)

J. Scott Tonigan, P.I.
Michael P. Bogenschutz, Co-Investigator
NIAAA (NIH)
Starting and stopping dates 04/15/2004-03/31/2009

Behavioral/Pharmacologic Treatment of Alcoholism (Project COMBINE)
University of New Mexico site, U10 AA011716-08
William R. Miller, P.I.
Michael P. Bogenschutz, Co-Investigator and Medical Director
09/30/1997-08/31/2006:

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study
Florian Birkmayer, P.I.
Michael P. Bogenschutz, Co-P.I.
Forrest Pharmaceuticals (investigator-initiated study)

On Site Behavioral Health Services
Michael P. Bogenschutz, P.I.
Ayudantes Inc., Santa Fe, NM
07/01/03-06/30/04

Safety and efficacy of Naltrel in treatment of alcohol dependence (Naltrel 99-03)
H. George Nurnberg, P.I.
Michael P. Bogenschutz, Co-P.I.
Drug Abuse Sciences.
2000-2002

A Double-blind Trial of Olanzapine in Patients with Borderline Personality Disorder
Michael P. Bogenschutz, P.I.
Eli Lilly & Co., (investigator-initiated study)
2000-2003

12-step facilitation for Dual Diagnosis Patients
Michael P. Bogenschutz, P.I.
UNM SOM Department of Psychiatry
2000-2003

Stigma and Rurality: Drug Abuse, HIV/STD and Mental Illness RO1:
Laura W. Roberts. P.I.
Michael P. Bogenschutz, Consultant
NIMH/NIDA (NIH)
1999-2003

Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients. :

Juan Bustillo, P.I.

Michael P. Bogenschutz, Co-Investigator

Eli Lilly (Investigator-initiated study)

1998-2000

Olanzapine added to mood stabilizers in the treatment of bipolar disorder (Protocol F1D-MC-HGFU)

H. George Nurnberg, P.I.

Michael P. Bogenschutz, Co-P.I.

Eli Lilly and Co.

1998-2000

Acamprosate in patients with alcohol dependence: a double-blind, placebo-controlled safety and efficacy study at two active dose levels (ACAMP/US/96.1)

P.I. H. George Nurnberg

Michael P. Bogenschutz, Co-P.I.

Lipha Pharmaceuticals

1997-1998

A double-blind, randomized comparison of olanzapine and haloperidol in the treatment of patients with comorbid schizophrenia spectrum disorder and active substance dependence

Michael P. Bogenschutz, P.I.

Eli Lilly and Co. (investigator-initiated study)

1997-2000:

A Pilot Study of the Role of Illness-related Beliefs in Comorbid Major Mental Illness and Substance Use Disorder (Dual Diagnosis)

Michael P. Bogenschutz, P.I.

UNM SOM Department of Psychiatry

1995-1996

Service

University, SOM, HSC administrative duties

- 11/2001-present: Vice Chair for Addiction Psychiatry, Department of Psychiatry, University of New Mexico School of Medicine
- 8/2001-present: Medical Director of Addiction Services
- 5/2000 8/2001: Director of Continuing Care Clinics, University of New Mexico Mental Health Center
- 8/1995-1/2003: Medical Director, Dual Diagnosis Program, University of New Mexico Mental Health Center
- 7/1998-3/2000: Co-Director of Partial Hospital Program, University of New Mexico Mental Health Center

University, SOM, HSC, department committees

- 2006-present: Member, HSC Research Allocation Committee
- 2006-present: Member, HSC Brain and Behavioral Illness Leadership Group
- 4/2005- present: Member, HSC Clinical Trials Center Steering Committee
- 4/2005 present: Member, CASAA Director Search Committee
- 6/2004-present: Member, Graduate Medical Education Operations Committee, UNM HSC
- 6/2004-present: Member, Residency Training Committee, Dept. of Psychiatry
- 4/2004-present: Member, Human Research Review Committee, University of New Mexico Health Sciences Center.
- 10/2001-5/2004: Member, Pharmacy and Therapeutics Committee, University of New Mexico Health Sciences Center.
- 1997-2000, and April 2003-present: Research Committee, Department of Psychiatry, University of New Mexico School of Medicine.
- 2000-2004: Member, Behavioral Health Information System Steering Committee, University of New Mexico Health Sciences Center.
- 1995-2002: Steering Committee on Native American Psychiatry, Department of Psychiatry, University of New Mexico School of Medicine.

Local, state, regional, national committees

- 2007-present: Member, State of New Mexico Governor's taskforce on compulsive gambling
- 10/2005-present: Member Publications Committee, NIDA Clinical Trials Network
- 3/2005-present: Member, Governor's Task Force on Compulsive Gambling, State of New Mexico

- 12/2004-present: Member, Executive Committee, NIDA Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS).
- 10/2002-9/2005: Member, Regulatory Affairs Subcommittee, NIDA Clinical Trials Network
- 1996: Chair, Detoxification Sub-committee of Program Model Committee, DWI Planning Council of City of Albuquerque, NM.
- 1995-1996: Member of advisory board to Native American Suicide Task Force which submitted a report on the subject to the US Congress April 1996.